2,182 Shares in AbbVie Inc. $ABBV Bought by Quantum Financial Partners LLC

Quantum Financial Partners LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,182 shares of the company’s stock, valued at approximately $549,000.

Several other large investors have also bought and sold shares of the stock. Litman Gregory Wealth Management LLC bought a new stake in shares of AbbVie in the 4th quarter valued at about $28,000. Imprint Wealth LLC increased its stake in shares of AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the period. Legacy Wealth Managment LLC ID raised its position in shares of AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares during the last quarter. IFC & Insurance Marketing Inc. bought a new position in shares of AbbVie during the fourth quarter worth about $31,000. Finally, WestEnd Advisors LLC lifted its stake in shares of AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the period. 70.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. HSBC restated a “buy” rating and set a $300.00 price target on shares of AbbVie in a report on Monday, July 6th. Weiss Ratings upgraded shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. Citigroup upped their price objective on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Finally, Bank of America increased their price objective on shares of AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $275.50.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Neuroscience growth is gaining momentum: AbbVie’s neuroscience franchise delivered strong first-half growth, with Parkinson’s treatment Vyalev accelerating. Potential approval and commercialization of tavapadon could provide another growth driver in the second half of 2026. Can ABBV’s Neuroscience Drugs Drive Growth in the Second Half of 2026?
• Positive Sentiment: Post-Humira diversification remains a key bullish theme: Analysts and investors point to resilient revenue growth from AbbVie’s next-generation immunology and aesthetics portfolio. Wolfe Research upgraded AbbVie on pipeline strength and valuation, while BNP Paribas Exane also expects the stock to rise. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Positive Sentiment: Recent operating performance supports the growth case: AbbVie’s reported first-quarter 2026 revenue increased 12.4% year over year, while adjusted EPS exceeded internal expectations despite an acquired research-and-development charge. Could AbbVie Inc. Post-Humira Transformation Drive the Next Phase of Growth?
• Neutral Sentiment: Pipeline updates add potential but remain clinical-stage catalysts: AbbVie is expanding Alzheimer’s research with ABBV-1758 and studying Rinvoq against Humira in rheumatoid arthritis, while real-world China data for upadacitinib in atopic dermatitis could help reinforce Rinvoq’s commercial position. AbbVie Steps Deeper Into Alzheimer’s
• Negative Sentiment: Risks include valuation and pipeline uncertainty: A comparison with Bristol-Myers Squibb highlighted that AbbVie trades at a considerably richer valuation. Separately, the partners clarified a setback in the Phase 3 epcoritamab lymphoma study, and Erste Group Bank lowered its AbbVie earnings estimates—both potential sources of caution. Could AbbVie Win as Genmab Faces a New Regulatory Test for Epcoritamab?

AbbVie Price Performance

Shares of NYSE:ABBV opened at $249.20 on Friday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47. The business’s 50-day moving average is $244.94 and its 200-day moving average is $226.12. The company has a market capitalization of $440.29 billion, a price-to-earnings ratio of 70.40, a P/E/G ratio of 0.83 and a beta of 0.30.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the prior year, the company earned $2.97 EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts anticipate that AbbVie Inc. will post 14.07 EPS for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio is presently 195.48%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.